Section 5: Patient Safety and Quality Assurance

5PSQ-134

PATIENTS’ SATISFACTION TOWARD PHARMACEUTICAL CARE AT A UNIVERSITY HOSPITAL

5PSQ-147

A SYSTEMATIC RISK ANALYSIS METHOD APPLIED TO THE MEDICAL DEVICES MANAGEMENT PROCESS IN A HOSPITAL PHARMACY

5PSQ-144

Development and validation of clinical rules to address risk prescriptions

5PSQ-058

EFFICACY AND MARGINAL COST OF TREATMENT WITH TOCILIZUMAB IN COVID-19 PATIENTS

5PSQ-082​

EFFECTIVENESS IN REAL LIFE OF BIOLOGICAL DRUGS USED IN MIGRAINE PROPHYLAXIS

5PSQ-145

MEDICINAL PLANTS USE AMONG TUNISIAN PATIENTS: PREVALENCE AND PERCEPTION

5PSQ-010

Identification of incorrect dosing of direct oral anticoagulants: an important intervention to improve patient safety

5PSQ-158​

Food and drink management as part of medicaton administration safety

5PSQ-148

TANDEM PROJECT: TRANSITIONS OF CARE AND MEDICATION RECONCILIATION IN HIGH-RISK PATIENTS

5PSQ-146

RISK MAPPING OF DRUG MANAGEMENT IN A PRISON

5PSQ-141

Personalized therapy for interstitial lung diseases in caused by ABCA3 mutations

5PSQ-135

NEW SECURITY WARNINGS FOR TOFACITINIB: ANALYSIS OF PATIENTS IN RISK

5PSQ-133

ANALYSIS OF REAL-LIFE DATA: OVERALL SURVIVAL AND PROGRESSION FREE SURVIVAL OF NIVOLUMAB AND ATEZOLIZUMAB IN NOT SMALL CELLS LUNG CANCER

5PSQ-130

DOSE BANDING OF INTRAVENOUS 5-FLUOROURACIL, OXALIPLATIN, PACLITAXEL AND GEMCITABIN: EVALUATION OF EFFICIENCY AND SAFETY SUBSEQUENT TO AN IMPLEMENTATION PROGRAMME

5PSQ-111

PHARMACEUTICAL INTERVENTION: AVOIDING INTERACTIONS BETWEEN ANTIRETROVIRALS AND VITAMIN SUPPLEMENTS/ ANTIACIDS

Pages